Table 3 Therapeutic targets in clinical trials targeting macrophages in cancers

CCL2

Centocor Research & Development, (Carlumab (CNTO 888)

NCT00992186

Prostate cancer

Phase II

CSF1

Novartis Oncology, (Lacnotuzumab (MCS110)

NCT02435680; (Carboplatin, gemcitabine)

Advanced triple-negative cancer

NCT01643850

Pigmented villonodular synovitis

NCT03694977; (PDR001)

Gastric cancer

TIE2

Karmanos Cancer Institute, (CEP-11981 (ESK981)

NCT04159896; (Nivolumab)

Prostate cancer

NCT03456804

Prostate cancer

TIE2

Bayer, (Regorafenib (BAY 73–4506)

NCT04170556 (Nivolumab); NCT04476329

Hepatocellular carcinoma

Arginase

Incyte, (INCB001158 (CB1158)

NCT02903914; (Pembrolizumab); NCT03314935; (Oxaliplatin, leucovorin, 5-fluorouracil, gemcitabine, cisplatin, paclitaxel); NCT03837509 (Daratumumab)

Advanced/metastatic solid tumors; Solid tumors; Multiple myeloma

CD40

Celldex Therapeutics, (CDX-1140)

NCT04491084; (CDX-301); NCT04364230

Non-small-cell lung cancer, lung cancer; Melanoma;

Genentech, Inc.Seagen Inc., (Dacetuzumab (SGN-40)

NCT00283101

Lymphocytic, chronic leukemia

NCT00435916

Large B-cell diffuse lymphoma, non-Hodgkin lymphoma

Novartis Pharmaceuticals, (Lucatumumab (HCD122)

NCT00670592

Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma

BTK

Pharmacyclics LLC, (Ibrutinib (PCI-32765)

NCT02599324

Renal cell, urothelial, gastric, colon, pancreatic adenocarcinoma

Phase II

NCT01752426; (heavy water (2H₂O)

Leukemia

NCT01236391

Mantle cell lymphoma

NCT01105247;

B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma

NCT01614821;

Waldenstrom’s macroglobulinemia

NCT01520519; (Rituximab)

Leukemia

NCT01109069;

B-cell lymphoma, chronic lymphocytic leukemia

NCT01217749; (Ofatumumab)

Chronic lymphocytic leukemia

NCT02403271; (Durvalumab)

Non-small-cell lung cancer, breast cancer, pancreatic cancer

NCT01646021; (Temsirolimus)

Mantle cell lymphoma

Phase III

NCT01855750; (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)

Lymphoma

Phase II

Pharmacyclics LLC

NCT01980628;

Marginal zone lymphoma, B-cell lymphoma

NCT01589302;

Prolymphocytic leukemia, small lymphocytic lymphoma, chronic lymphocytic leukemia

NCT01325701;

Diffuse large cell B lymphoma

NCT01578707; (Ofatumumab)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

Phase III

NCT01722487; (Chlorambucil)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

NCT0243666;8 (Gemcitabine, nab-paclitaxel)

Metastatic pancreatic adenocarcinoma

NCT01980654; (Rituximab)

Follicular lymphoma, B-cell lymphoma, non-Hodgkin’s lymphoma

Phase II

NCT01973387; (Rituximab)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

Phase III

NCT01611090; (Bendamustine, hydrochloride, rituximab)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

NCT02401048; (MEDI4736)

Diffuse large B-cell lymphoma, follicular lymphoma

Phase II

NCT02639910; (Tafasitamab, idelalisi, venetoclax)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

NCT02902965; (Bortezomib dexamethasone)

Multiple myeloma

NCT01744691

Chronic lymphocytic leukemia with 17p deletion, small lymphocytic lymphoma with 17p deletion

NCT02264574; (Obinutuzumab, chlorambucil)

Chronic lymphocytic leukemia, small-cell lymphoma

Phase III

NCT02514083; (Fludarabine)

Chronic lymphocytic leukemia, small lymphocytic lymphoma

Phase II

Acerta Pharma BV, (Acalabrutinib (ACP-196)

NCT02180724

Waldenström macroglobulinemia

NCT02213926

Mantle cell lymphoma

BeiGene, (Zanubrutinib (BGB-3111)

NCT03206970

Mantle cell lymphoma

NCT03206918

Chronic lymphocytic leukemia, small lymphocytic lymphoma

CSF1R

Plexxicon, (Pexidartinib (PLX-3397)

NCT01596751; (Eribulin)

Metastatic breast cancer

Phase II

Array Biopharma, (ARRY-382)

NCT02880371; (Pembrolizumab)

Advanced solid tumors

Eli Lilly (IMC-CS4(LY3022855)

NCT03101254; (Vemurafenib cobimetinib)

Melanoma

Five Prime Therapeutics (Cabiralizumab (FPA008))

NCT02471716

Tenosynovial giant cell tumor

NCT03927105

Peripheral T-cell lymphoma

NCT04331067; (Nivolumab)

Triple-negative breast cancer

Hoffman La Roche (Emactuzumab (RO5509554))

NCT03708224 (Atezolizumab)

Advanced head and neck squamous cell carcinoma

NCT03193190; (Additional therapies)

Pancreatic ductal adenocarcinoma

Deciphera Pharmaceuticals LLC (DCC-3014)

NCT03069469

Advanced malignant neoplasm

Syndax (SNDX-6532)

NCT04301778; (Durvalumab)

Unresectable intrahepatic cholangiocarcinoma

Plexxikon (PLX3397)

NCT02584647; (Sirolimus)

Sarcoma, nerve-sheath tumors

NCT02452424; (Pembrolizumab)

Advanced melanoma and solid tumours

Novartis (BLZ945)

NCT02829723PDR001 (anti-PD1)

CD47

Gilead Sciences (Magrolimab (Hu5F9-G4))

NCT04541017 (Mogamulizumab)

T-cell lymphoma

NCT04435691 (Azacitidine, venetoclax)

Acute myeloid leukemia

NCT03869190 (Atezolizumab, enfortumab, vedotin, niraparib)

Urothelial carcinoma

NCT02953509 (Rituximab, gemcitabine, oxaliplatin)

Non-Hodgkin lymphoma

NCT04313881 (Azacitidine)

Myelodysplastic syndromes

Phase III

Arch Oncology (AO-176)

NCT03834948 (Paclitaxel)

Solid tumor

Phase II

NCT04445701 (Bortezomib, dexamethasone)

Multiple myeloma

CCR2

Bristol-Myers Squibb (BMS-813160)

NCT03184870 (Chemotherapy or nivolumab)

Colorectal/pancreatic cancer

NCT03496662 (Nivolumab abraxane, gemcitabine)

Pancreatic cancer

NCT03767582 (Radiation therapy, nivolumab, GVAX)

Pancreatic cancer

NCT04123379 (Nivolumab, BMS-986253)

Non-small-cell lung cancer, hepatocellular carcinoma

NCT02996110 (Nivolumab, ipilimumab, relatlimab, BMS-986205)

Advanced cancer

ChemoCentryx (CCX872-B)

NCT03778879 (Radiation therapy)

Pancreatic cancer

Millenium (MLN1202)

NCT01015560

Bone metastases

Pfizer (PF-04136309)

NCT02732938 (Nab-paclitaxel, Gemcitabine)

Metastatic pancreatic ductal adenocarcinoma